The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study

Israel Manzanedo Romero; Fernando Pereira Pérez; Ángel Serrano del Moral; Estibaliz Perez Viejo; B. Martínez Torres; Lucía Carrión Álvarez; Julia Calzas Rodríguez

Ayuda

The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study

I. Manzanedo ^[1] ; F. Pereira ^[1] ; Á. Serrano ^[1] ; E. Pérez-Viejo ^[1] ; B. Martínez-Torres ^[1] ; L. Carrión ^[1] ; J. Calzas ^[1]
1. [1] Hospital de Fuenlabrada
  
  Hospital de Fuenlabrada
  
  Fuenlabrada, España
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 10, 2019, págs. 1357-1363
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Purpose Our main aim is to analyze the survival results in women operated on for advanced ovarian cancer with two different HIPEC regimens (cisplatin plus doxorubicin versus paclitaxel).
  
  Patients and methods A prospective cohort of patients with stage IIIC or IV epithelial ovarian cancer operated on with cytoreductive surgery and HIPEC, from October-2008 to February-2016, was retrospectively analyzed. The two drugs used, cisplatin/doxorubicin (Group A) and paclitaxel (Group B), were compared.
  
  Results Forty-one patients were treated with cytoreductive surgery and HIPEC; 19 patients (46%) were in Group A and 22 (54%) were in Group B. The extent of peritoneal disease was comparable between groups (Peritoneal Cancer Index of 10 in Group A versus PCI of 12.5 in Group B). There were no differences in morbidity between groups, with a severe morbidity (Dindo–Clavien III or IV) of 36.8% versus 27.3%, respectively. There was no postoperative mortality. Median follow-up was 39 months. Median overall survival was 79 months. Overall survival at 3 years in Group A was 66% versus 82.9% in Group B (p = 0.248). Incomplete cytoreduction (macroscopic residual tumour after surgery) was identified as the only independent factor that influenced overall survival (HR 12.30, 95% CI 1.28–118.33, p = 0.03). The cytostatic used in HIPEC had no influence in overall survival.
  
  Conclusion The cytostatic used in HIPEC did not have a negative effect in the prognosis of patients with advanced ovarian cancer.